Drug intelligence / Profile preview

frentizole-Tubulin-Small molecule-Unknown-Cancer

Development stage: Unknown
Modality: Small Molecules

Overview

No specific information regarding the drug 'frentizole-Tubulin-Small molecule-Unknown-Cancer' was found in the provided context. The context discusses preclinical broad-spectrum antiviral compounds, specifically 3C-like protease (3CLpro) inhibitors, developed by Kansas State University and licensed by Cocrystal Pharma, for the treatment of coronaviruses and noroviruses.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on frentizole-Tubulin-Small molecule-Unknown-Cancer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on frentizole-Tubulin-Small molecule-Unknown-Cancer.

Explore the full profile